Efficacy and safety of nebulised amphotericin B (NAB) in severe asthma with fungal sensitisation (SAFS) and allergic bronchopulmonary aspergillosis (ABPA)

References

• Harrison B, Stephenson P, Mohan G, Nasser S. An ongoing confidential enquiry into asthma deaths in the eastern region of the UK, 2001–2003. Prim Care Respir J 2005;14:303–313
   PubMedGoogle Scholar
• Goldacre MJ, Duncan ME, Griffith M. Death rates for asthma in English populations 1979–2007: comparison of underlying cause and all certified causes. Public Health 2012;126:386–393
   Google Scholar
• Ismaila AS, Sayani AP, Marin M, Su Z. Clinical, economic, and humanistic burden of asthma in Canada: a systematic review. BMC Pulm Med 2013;13:70
   PubMed Web of Science ®Google Scholar
• Donnelly SC, McLaughlin H, Bredin CP. Period prevalence of allergic bronchopulmonary mycosis in a regional hospital outpatient population in Ireland 1985–88. Ir J Med Sci 1991;160:288–290
   PubMed Web of Science ®Google Scholar
• Eickmeier O, et al. Immune response, diagnosis and treatment of allergic bronchopulmonary aspergillosis in cystic fibrosis lung disease. Curr Pharm Des 2013;19:669–3678
   Google Scholar
• Niels Kleinkauf PEV, Maiken C, Arendrup PJD, Cuenca-Estrella M, Fraaije B, Melchers WJG, Kema GHJ, et al. European Centre for Disease Prevention and Control. Risk assessment on the impact of environmental usage of triazoles on the development and spread of resistance to medical triazoles in Aspergillus species. Stockholm: European Centre for Disease Prevention and Control (ECDC); 2013
   Google Scholar
• Clayton DE, Busse WW. Development of allergic bronchopulmonary aspergillosis during treatment of severe asthma with systemic corticosteroids. J Allergy Clin Immunol 1981;67:243–246
   PubMed Web of Science ®Google Scholar
• Wark PA, Gibson PG, Wilson AJ. Azoles for allergic bronchopulmonary aspergillosis associated with asthma. Cochrane Database Syst Rev 2003;(3):CD001108
   Google Scholar
• Denning DW, et al. Randomized controlled trial of oral antifungal treatment for severe asthma with fungal sensitization: the Fungal Asthma Sensitization Trial (FAST) study. Am J Respir Crit Care Med 2009;179:11–18
   PubMed Web of Science ®Google Scholar
• Chishimba L, et al. Voriconazole and posaconazole improve asthma severity in allergic bronchopulmonary aspergillosis and severe asthma with fungal sensitization. J Asthma 2012;49: 423–433
   PubMed Web of Science ®Google Scholar
• Agbetile J, Bourne M, Fairs A, Hargadon B, Desai D, Broad C, Morley J, et al. Effectiveness of voriconazole in the treatment of Aspergillus fumigatus-associated asthma (EVITA3 study). J Allergy Clin Immunol 2014;134:33–9
   PubMed Web of Science ®Google Scholar
• Suissa S, Patenaude V, Lapi F, Ernst P. Inhaled corticosteroids in COPD and the risk of serious pneumonia. Thorax 2013;68:1029–1036
   PubMed Web of Science ®Google Scholar
• Skov M, Patenaude V, Lapi F, Ernst P. Iatrogenic adrenal insufficiency as a side-effect of combined treatment of itraconazole and budesonide. Eur Respir J 2002;20:127–133
   PubMed Web of Science ®Google Scholar
• Monforte V, et al. Nebulized liposomal amphotericin B prophylaxis for Aspergillus infection in lung transplantation: pharmacokinetics and safety. J Heart Lung Transplant 2009;28:170–175
   PubMed Web of Science ®Google Scholar
• Proesmans M, Vermeulen F, Vreys M, De Boeck K. Use of nebulized amphotericin B in the treatment of allergic bronchopulmonary aspergillosis in cystic fibrosis. Int J Pediatr 2010;2010:376287
   PubMedGoogle Scholar
• Godet C, Meurice JC, Roblot F, Kauffmann-Lacroix C, Verdaguer M, Frat JP, Cadranel J. Efficacy of nebulised liposomal amphotericin B in the attack and maintenance treatment of ABPA. Eur Respir J 2012;39:1261–1263
   PubMed Web of Science ®Google Scholar
• Laoudi Y, Paolini JB, Grimfed A, Just J. Nebulised corticosteroid and amphotericin B: an alternative treatment for ABPA? Eur Respir J 2008;31:908–909
   PubMed Web of Science ®Google Scholar
• Leon EE, Craig TJ. Antifungals in the treatment of allergic bronchopulmonary aspergillosis. Ann Allergy Asthma Immunol 1999;82:511–516; quiz 516–519
   PubMed Web of Science ®Google Scholar
• Casey P, Garrett J, Eaton T. Allergic bronchopulmonary aspergillosis in a lung transplant patient successfully treated with nebulized amphotericin. J Heart Lung Transplant 2002;21:1237–1241
   PubMed Web of Science ®Google Scholar
• Slobbe L, Boersma E, Rijnders BJ. Tolerability of prophylactic aerosolized liposomal amphotericin-B and impact on pulmonary function: data from a randomized placebo-controlled trial. Pulm Pharmacol Ther 2008;21:855–859
   Google Scholar
• Hayes D Jr, Murphy BS, Lynch JE, Feola DJ. Aerosolized amphotericin for the treatment of allergic bronchopulmonary aspergillosis. Pediatr Pulmonol 2010;45:1145–1148
   PubMed Web of Science ®Google Scholar
• Patterson R, Greenberger PA, Halwig JM, Liotta JL, Roberts M. Allergic bronchopulmonary aspergillosis. Natural history and classification of early disease by serologic and roentgenographic studies. Arch Intern Med 1986;146:916–918
   PubMedGoogle Scholar
• Patterson R, Greenberger PA, Harris KE. Allergic bronchopulmonary aspergillosis. Chest 2000;118:7–8
   PubMed Web of Science ®Google Scholar
• Denning DW, O’Driscoll BR, Hogaboam CM, Bowyer P, Niven RM. The link between fungi and severe asthma: a summary of the evidence. Eur Respir J 2006;27:615–626
   PubMed Web of Science ®Google Scholar
• Levy ML, Thomas M, Small I, Pearce L, Pinnock H, Stephenson P. Summary of the 2008 BTS/SIGN British Guideline on the management of asthma. Prim Care Respir J 2009;18:S1–S16
   PubMedGoogle Scholar
• Ricketti AJ, Greenberger PA, Mintzer RA, Patterson R. Allergic bronchopulmonary aspergillosis. Arch Intern Med 1983;143:1553–1557
   PubMedGoogle Scholar
• Juniper EF, Guyatt GH, Ferrie PJ, Griffith LE. Measuring quality of life in asthma. Am Rev Respir Dis 1993;147:832–838
   PubMed Web of Science ®Google Scholar
• Dubois J, Bartter T, Gryn J, Pratter MR. The physiologic effects of inhaled amphotericin B. Chest 1995;108:750–753
   PubMed Web of Science ®Google Scholar
• Erjavec Z, Woolthuis GM, de Vries-Hospers HG, Sluiter WJ, Daenen SM, de Pauw B. Tolerance and efficacy of amphotericin B inhalations for prevention of invasive pulmonary aspergillosis in haematological patients. Eur J Clin Microbiol Infect Dis 1997;16:364–368
   PubMed Web of Science ®Google Scholar
• Rijnders BJ, Cornelissen JJ, Slobbe L, Becker MJ, Doorduijn JK, Hop WC. Aerosolized liposomal amphotericin B for the prevention of invasive pulmonary aspergillosis during prolonged neutropenia: a randomized, placebo-controlled trial. Clin Infect Dis 2008;46:1401–1408
   PubMed Web of Science ®Google Scholar
• Gryn J, Goldberg J, Johnson E, Siegel J, Inzerillo J. The toxicity of daily inhaled amphotericin B. Am J Clin Oncol 1993;16:43–46
   PubMed Web of Science ®Google Scholar
• Kamalaporn H, Leung K, Nagel M, Kittanakom S, Calvieri B, Reithmeier RA, Coates AL, et al. Aerosolized liposomal amphotericin B: a potential prophylaxis of invasive pulmonary aspergillosis in immunocompromised patients. Pediatr Pulmonol 2013;49:574–80
   Google Scholar
• Allen SD, Sorensen KN, Nejdl MJ, Durrant C, Proffit RT. Prophylactic efficacy of aerosolized liposomal (AmBisome) and non-liposomal (Fungizone) amphotericin B in murine pulmonary aspergillosis. J Antimicrob Chemother 1994;34:1001–1013
   PubMed Web of Science ®Google Scholar